*Sponsored
Market Crux Initiates Coverage On (INBS) Starting This
Morning—Tuesday, July 15, 2025
And Here's Why…
With Fewer Than 7M Shares In The Float, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Has The Potential To Witness Significant Swings If Demand Begins To Shift.
Highlighted In Today's Report From Ladenburg Thalmann, (INBS) Received A $12 Target, Which Suggests Over 600% Upside Potential.
Fingerprint-Based Screening Devices From (INBS) Are Already In Use Across 450+ Customer Accounts And 1,000+ Active Deployments.
(INBS) Reported A 148% Increase In Annual Revenue And A 32.6% Boost In Gross Profit Alongside A Growing Customer Base.
With FDA 510(k) Clearance Anticipated In The First Half Of 2025, (INBS) Is Preparing For U.S. Launch Later This Year.
Pull Up (INBS) This Morning While It's Still Early…
July 15, 2025 Early Tuesday's Watchlist | See Why (INBS) Just Hit Our Radar This Morning Dear Reader, Please tell me you're watching (INBS) right now. (INBS) tapped $2.18 this morning on an approximate 26% overnight move from yesterday's $1.73 close. Also, (INBS) surpassed every major moving average tracked by Barchart, momentum is building fast—and the technicals on TradingView are lighting up. Earlier today, breaking news out of (INBS) hit the wire. Intelligent Bio Solutions Inc. (NASDAQ: INBS) just leveled up its product game—again. This morning, the company unveiled the SmarTest® Patch, a next-gen wearable that detects dru-gs through sweat for up to 10 days. It's discreet, tamper-evident, and a powerful complement to INBS's flagship fingerprint system—pushing the company deeper into justice, rehab, and long-window testing markets. If this is the first time you're hearing about (INBS), keep reading to quickly get up to speed. Every now and then, something slips beneath the surface—quiet, overlooked, but loaded with potential. No media buzz. No headline rush. Just a low-key release from one of the street's oldest firms… and a price target bold enough to stop us mid-scroll. The company? Still trending under $2 and still under most radars. But with a tight float, real-world traction, and a new $12 target from Ladenburg Thalmann—it may not stay quiet for long. That company is Intelligent Bio Solutions Inc. (NASDAQ: INBS)—a sub-$12M profile with fewer than 7M shares in the float and a fingerprint-based screening system already deployed across 450+ customers in 24 countries. And earlier today (July 14, 2025), analyst Jeffrey S. Cohen lit it up with a $12 target—which suggests over 600% upside from its recent $1.70 range. 
Few Know What This Fingerprint Tech Is Quietly Disrupting
Behind the Scenes…
When people think of screening, they still imagine urine samples, delays, and uncomfortable procedures. But one company is rewriting that playbook—using fingerprint sweat instead of saliva, urine, or needles to screen for commonly misused substances. This isn't a future concept. The system is already active in the field, with over 1,000 devices in use and aiming to expand into the U.S. later this year. The process? Just a fingerprint. The turnaround? Under 10 minutes. And in an FDA-submitted method comparison study, it delivered 94.1% accuracy and 100% specificity for opiates. For employers seeking safer, faster, and more discreet screening, this fingerprint-based system may not just be an upgrade—it could redefine the standard. Revenue Growth, Expanding Margins, and U.S. Market Entry Ahead
For the quarter ending December 31, 2024, the company posted: - 32.6% year-over-year growth in gross profit
- Gross margin improvement to 38.5%, up from 27.7%
- 19 new customer accounts added during the quarter
For the full fiscal year ending June 30, 2024, total revenue reached $3.11M, marking a 148% year-over-year increase. Recurring cartridge sales continue to scale steadily, reinforcing a razor/razor-blade model built for sustained usage and long-term volume growth. 
U.S. Launch Expected Following 510(k) Submission
The company filed its 510(k) submission in December 2024 and anticipates U.S. clearance in the first half of 2025, with a commercial launch planned for the second half—starting with opiate detection and expanding from there. The U.S. workplace is a primary focus.
Substance misuse costs the nation over $400B annually, and more than 70% of those affected are employed. Meanwhile, test positivity rates have risen for five consecutive years. Why Fingerprint Screening?
This approach removes many of the burdens tied to traditional methods: - No gender-specific supervision
- No hazardous waste
- No special training required
- No waiting for a sample
It's clean, fast, and discreet. Some users report it cuts costs by 50%—eliminating both lab fees and employee downtime in the process. From Europe to the U.S.—With Data to Back It Up
(INBS) already serves real-world customers across the U.K. and other international markets, including P&O Ferries and industrial service providers. These aren't test pilots—they're live deployments. Recent clinical work supports the company's expansion: - In a PK study, fingerprint sweat tracked closely with codeine levels in blood and saliva.
- In a 135-subject comparison against LC-MS/MS lab methods, the fingerprint system's results matched closely—validating its reliability.
Recent Developments
July 10, 2025 — INBS to Present PK Study at ADLM 2025 Clinical Lab Expo
(INBS) will present human pharmacokinetic (PK) data at ADLM 2025 in Chicago, highlighting the accuracy of fingerprint sweat for detecting codeine ingestion. Results showed strong correlation with blood and saliva samples, positioning INBS's technology as a credible, non-invasive alternative for diagnostic testing. The expo appearance signals increasing validation and visibility within the clinical lab and diagnostics space.
See Full News Release Here June 25, 2025— INBS and Spjotgard Drive Fingerprint Drug Testing Across Scandinavia
Through a growing partnership with distributor Spjotgard, (INBS) is rapidly expanding its footprint in Sweden, Norway, and Denmark. Customers across education, logistics, and the justice system are adopting the technology for its speed, hygiene, and ease of use. With more than 450 accounts globally, (INBS) is gaining traction as Scandinavia pursues modern, less invasive screening approaches. See Full News Release Here June 18, 2025 — INBS Launches Fingerprint Testing Across 20+
Australian Sites
(INBS) announced its largest APAC rollout to date, deploying its system across 20+ sites for Managed Waste Service in New South Wales. The implementation allows on-site, in-house drug testing for safety compliance—eliminating the need for outsourced testing and enabling real-time decisions. It underscores (INBS)'s growing presence in field-based industries where speed and portability are mission-critical. See Full News Release Here June 11, 2025 — INBS Expands U.S. Forensic Presence Through
SMARTOX Partnership
(INBS) has surpassed 7,000 tests through SMARTOX, a Texas-based screening partner serving corrections and rehab clients. With more than 50 devices deployed and 1,500+ tests conducted in 2024 alone, the U.S. forensic footprint continues to grow. Simultaneously, (INBS) is actively pursuing FDA clearance for broader U.S. use in workplace screening. This dual-track strategy combines market penetration with regulatory momentum. See Full News Release Here These developments demonstrate a clear execution path—from technology deployment to global scalability—and position (INBS) for increased visibility and adoption in key international markets. Looking Ahead…
(INBS) may still be flying under the radar—but its real-world deployments, accelerating revenue, and active 510(k) submission suggest it's operating on a different level than peers still buried in research and development. With fewer than 7M shares in the float, a recurring-revenue cartridge model, and growing demand for modern workplace screening, this company appears to be on the cusp of something bigger. Fingerprinting has long been tied to identity. Now, it's quietly becoming a fast, accurate window into recent substance exposure—without needles, cups, or lab delays. Whether that transformation redefines the category or simply carves out a dominant niche, one thing is clear: the foundation is already being laid. The tech works. The infrastructure is scaling. And the regulatory wheels are turning. Add in the structural tailwinds—and the signals are hard to ignore. That's why (INBS) is firmly locked on our radar heading into Tuesday morning 7 Reasons Why (INBS) is Topping Our Watchlist This
Morning—Tuesday, July 15, 2025…
1. Analyst Target: Earlier yesterday, on July 14, 2025, a senior analyst from one of the country's oldest firms issued a $12 target on (INBS)—which suggests more than 600% upside potential from its recent $1.70 range.
2. Low Float: With fewer than 7M shares listed in the float and a market cap under $12M, (INBS) has the kind of structure that has historically witnessed significant swings if demand begins to shift. 3. Real Tech, Already in Use: This isn't a concept-stage company. Its fingerprint-based screening devices are already deployed across 450+ customer accounts—with over 1,000 systems in the field and international users actively relying on the platform. 4. Explosive Revenue Growth: (INBS) reported a 148% jump in annual revenue and a 32.6% increase in gross pro-fit—alongside margin expansion and a growing customer base, all pointing to consistent operational progress. 5. U.S. Launch Pending: (INBS) is preparing for a second-half 2025 rollout following an active FDA 510(k) submission filed in December 2024. 6. Expanding Global Reach: In just the last few months (INBS) launched multilingual support (Arabic, Spanish, Italian), localized its digital presence, and presented at a key industry conference—reinforcing its focus on real-world visibility and adoption across diverse regions. 7. Breakthrough Simplicity: Unlike traditional methods that require supervision, lab delays, and biological waste management, (INBS) offers non-invasive fingerprint-based testing with results in under 10 minutes. That kind of simplicity could change expectations for workplace and field-based screening environments. Potential catalysts are stacking up. And the story is still under the radar for most people. (INBS) could be walking into the spotlight. Take a Look at (INBS) This Morning While It's Still Early…
See (INBS)'s Corporate Presentation Here With real-world adoption already underway, multilingual expansion accelerating, and a float tight enough to catch notice when attention shifts—Intelligent Bio Solutions Inc. (NASDAQ: INBS) is showing signs of a company moving with purpose. Backed by a bold $12 target from a senior analyst, consistent year-over-year growth, and a pending U.S. entry in 2025, the pieces are lining up at a time when most are still catching up to the story. We have all eyes on (INBS) this morning. Take a look at (INBS) while it's still early. (INBS) tapped $2.18 this morning on an approximate 26% overnight move from yesterday's $1.73 close. Also, (INBS) surpassed every major moving average tracked by Barchart, momentum is building fast—and the technicals on TradingView are lighting up Are you watching this yet? Keep a lookout for my next update—it could be out any moment. Gary Silver
Managing Editor, Market Crux
| 
No comments:
Post a Comment